E. James Hutchens, Chief Executive Officer
Jim Hutchens is a proven entrepreneur with over 30 years of experience in general and marketing management in the medical technology industry. Mr. Hutchens also served as a Managing Partner in Origin Partners, a $55 million early stage, venture capital fund. As the founder and CEO of Microsurge Inc., a venture-backed, minimally invasive surgery company, he assembled a management team, guided the company’s products through the regulatory process, hired a sales and marketing team, drove revenues to an annual run rate of over $10M and sold the company. As the founder and CEO of Choice Therapeutics, an advanced wound-care company, Mr. Hutchens implemented similar tactics and, with revenue of $2M sold the company to Alliqua Biomedical a NASDAQ list company. At Microvasive Endoscopy, a division of Boston Scientific, revenues rose from $300,000 to over $20 million during his tenure as Vice President, Marketing and Sales. Mr. Hutchens has also served as a senior executive at Smith & Nephew, Millipore, and CR Bard. He is a former member of the Board of Directors of the Brigham and Womens/ Faulkner Hospital. He holds a BS in Business Administration from Boston University.
Jorge Avelino, Chief Financial Officer
Mr. Avelino joined the Issuer in February 2005 as a financial consultant responsible for the accounting department and the Company’s financial reporting requirements. In March 2007, he was appointed Chief Financial Officer. He has a Business Administration degree from the University of Ateneo, Manila, and over 30 years of accounting and financial management experience in both the private and public sectors. Since 1986 Mr. Avelino has dealt with start-up ventures and public companies involved in the resource and high-tech industries. Prior to dealing with public companies, Mr. Avelino was the general accountant for a Vancouver manufacturing & retail company in the forest industry. He has served as a director or officer of various companies.
Michael G. Vergano, Director of Operations
Michael Vergano has been president of The Harvest Group Inc. since 1998, where he has provided project management, product development, packaging, quality systems, operations, manufacturing engineering, and system/process design and validation services for start-ups as well as major medical corporations. His medical device experience includes the gynecology, laparoscopic surgery, GI endoscopy, dental imaging and implants, wound care, cardiology, urinary incontinence and orthobiologic regenerative technologies markets. Prior to 1998, Mr. Vergano was Director of Operations and Product Development at Apple Medical, Inc. Prior to Apple Medical, he served in engineering management positions for Ciba Corning Diagnostics, Microsurge, Inc. and Boston Scientific Corporation. At Boston Scientific, Mr. Vergano also achieved top performance recognition as a sales territory manager for its Microvasive GI Endoscopy Division, the same division for which he served in engineering management capacities for the prior five years. He is the holder of 11 medical device patents. Mr. Vergano holds a Bachelor of Science in Mechanical Engineering from Tufts University.
Stephen Ruggles, Director of Quality Assurance and Regulatory Affairs
Stephen Ruggles has over 30 years of experience in domestic and international regulatory affairs, operations management, manufacturing quality assurance, R&D, and supply chain management for early stage companies and large multinationals. As Director of QA / RA for Cambridge Endoscopic Devices, Mr. Ruggles led the effort to earn and maintain ISO 13485 registration, CE Mark, and compliance with Japan’s jPAL. Prior to Cambridge Endo, he served eight years at Becton Dickinson and Company as a Supply Chain Quality Engineer, R&D Quality Engineer, Quality Manager and Regulatory Compliance Manager. Prior to Becton Dickinson, Mr. Ruggles spent 13 years in progressively more responsible Operations Management positions in seven plants for C R Bard’s Angiography, Angioplasty, and Cardiovascular divisions. He holds a BBA from the University of Massachusetts at Amherst and a M.S. in Regulatory Affairs from The Massachusetts College of Pharmacy and Health Sciences.
Thom McMahon, Director of Sales
Thom Mahon has been involved in medical device sales and marketing for over 35 years. Thom is currently the owner and president of Urolaze, an independent urology focused distribution company. Thom’s team is responsible for Siemens C-Aim and lasers as well as American Medical Systems prostate lasers and other products. He has spent over 25 years with Karl Storz in various sales and marketing positions and was the number one sales representative for over 10 years. Storz has over 100 salespeople and is the leading supplier of the endoscopes. Thom also held a senior sales position at Richard Wolf in the Northeast Mid-Atlantic regions.
Stavros G. Demos, Ph.D., Technical Scientific Advisor
Stavros Demos, Ph.D., has recently accepted the position of Senior Scientist and Group Leader of the Optical Materials Group at the University of Rochester Laboratory for Laser Energetics (LLE) in New York. Previously a scientist at Lawrence Livermore National Laboratory in the Physical and Life Sciences Directorate, Dr. Demos also held the position of Adjunct Associate Professor at the Department of Urology at the University of California at Davis (UCD) and served as a member of the scientific staff at the National Science Foundation Center of Biophotonics Science and Technology at UC Davis. He received his B.S. in physics from the University of Ioannina, Greece, and his Ph.D. in physics in 1993 from the City University of New York. His research interests are concentrated in the field of biomedical optics and the interaction of materials with high power laser pulses. He is working to develop instrumentation for in vivo detection of disease and monitoring of therapeutic intervention. Dr. Demos has published over 120 articles in refereed journals and holds 20 patents.
Ralph deVere White, M.D., Medical Advisor
Dr. deVere White is Associate Dean for Cancer Programs at UC Davis School of Medicine and Director of the UC Davis Comprehensive Cancer Center where he is also a Distinguished Professor of Urology. He received his medical degree from Dublin University in Dublin, Ireland, and completed an internship and residencies in surgery and urology at St. Vincent’s Hospital in Dublin and at Duke University Medical Center in Durham, NC. The author of more than 300 peer-reviewed scientific articles and book chapters, Dr. deVere White serves on the editorial boards of six international scientific journals. His current research efforts focused on the molecular events that govern the response of prostate and bladder cancer to targeted therapies, the biomolecular mechanisms that make some prostate cancers more virulent than others, and new methods of diagnosing and treating prostate cancer. He is the immediate past president-elect of the Society of Urologic Oncology, a member of the Clinical Society of Genitourinary Surgeons and an elected member of the prestigious American Association of Genitourinary Surgeons. He has been named multiple times as one of “The Best Doctors in America” and is one of four urologists serving as a volunteer consultant to the American Cancer Society’s on-line “Experts Answers” bulletin board for questions about prostate cancer.
Edward M. Messing, M.D., Medical Advisor
Dr. Edward Messing, Chief of Urology at the University of Rochester Medical Center, has joined Imagin’s Scientific Board of Advisors. Dr. Messing is a renowned expert in the diagnosis and treatment of cancers of the bladder, prostate, kidney, and other genitourinary organs. He has conducted extensive research in the basic biology of bladder and prostate cancers and has been the principal investigator on numerous clinical studies for the detection, prevention and treatment of genitourinary cancers. Dr. Messing received his M.D. degree from New York University, performed his surgery training at NYU-Bellevue Hospital and his Urology Residency at Stanford University. He was Director of the Urologic Oncology Program at the University of Wisconsin and assumed his current position at the University of Rochester School of Medicine and Dentistry in September 1995.
Dr. Messing has been involved in multiple clinical studies relevant to Imagin’s focus. Having both Dr. Messing and Dr. Stavros Demos, the inventor of the i/Blue, at the same institution, is a major advantage that will help drive Imagin’s development and clinical trial programs.
Liam J. Hurley, M.D., FACS, Medical Advisor
Dr. Hurley obtained his Bachelor of Arts degree from Harvard University and his M.D. from Boston University School of Medicine. After spending three years in the U.S. Navy, he completed a General Surgery Residency at St. Elizabeth’s Medical Center of Boston and his Urology Residency at the Lahey Clinic in Burlington, MA. He is trained as an adult and pediatric urologist with expertise in genitourinary oncology. Dr. Hurley is a private practice community urologist who has clinical affiliations with Tufts New England Medical Center and Lahey Clinic. Other accomplishments include launching The Boston Urologic Society, serving on the Executive Committee for the Massachusetts Association of Practicing Urologists, and presiding as the Eastern Massachusetts representative to the New England Section of the AUA.
Dr. Hurley is Board certified in Urology and is a Fellow of the American College of Surgeons. In 2006, he was chosen as one of Boston ‘s “TOP DOCTORS” by Boston Magazine.
Roger Buckley, M.D. Member, Medical Advisor
Dr. Roger Buckley is the Division Head of Urology at North York General Hospital in Toronto, where he has held various positions 1985, and is considered a top urologist in Canada. He has been vice president and president of the Medical Staff Association at NYGH and a member of the Board of Governors. Dr. Buckley conceptualized and opened the Gale and Graham Wright Prostate Center at NYGH in 2007, the first prostate center in the province to offer timely diagnosis, information, expertise and resources for prostate cancer in a community hospital setting. He also developed and has chaired the International Bladder Cancer Group (IBCG) from 2006-2016, a consortium of American, Canadian and European Union countries whose mission is to improve the diagnosis, prevention, and treatment of bladder cancer through the application of biologic markers. He is currently vice president of the IBCG, and as a member, has co-authored numerous peer-reviewed articles on bladder cancer. He has an ongoing interest in bladder cancer and prostate research and education. Dr. Buckley received his M.D. from the University of Toronto medical school where he also completed his urological Residency and Fellowship.